Fulminant hepatitis after infliximab in a patient with hepatitis B virus treated for an adult onset still's disease.
Infliximab, a chimeric anti-tumor necrosis factor-alpha monoclonal antibody, has been demonstrated to be efficient and safe in patients with active rheumatoid arthritis and in the management of severe bouts of Crohn's disease. However, the safety of infliximab has not been evaluated in patients infected with hepatitis B virus. We report the case of a 28-year-old woman, with a positive hepatitis B virus surface antigen, who developed fulminant hepatitis 2 weeks after receiving a second infliximab infusion for a refractory adult onset Still's disease.
Michel
Marc
M
Service de Médecine Interne, Hôpital Henri-Mondor, Créteil, France. marc.michel@hmn.ap-hop-paris.fr
Duvoux
Cristophe
C
Hezode
Cristophe
C
Cherqui
Daniel
D
D000328:Adult; D000911:Antibodies, Monoclonal / Q000009:adverse effects*; D018501:Antirheumatic Agents / Q000009:adverse effects*; D005260:Female; D006509:Hepatitis B / Q000150:complications / Q000473:pathology; D006801:Humans; D000069285:Infliximab; D008099:Liver / Q000187:drug effects / Q000473:pathology; D017093:Liver Failure / Q000139:chemically induced* / Q000473:pathology; D016706:Still's Disease, Adult-Onset / Q000150:complications / Q000628:therapy*
D000911:Antibodies, Monoclonal; D018501:Antirheumatic Agents; D000069285:Infliximab